Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Immuron (IMRN) Other Non Operating Income (2018 - 2024)

Immuron's quarterly Other Non Operating Income came in at $48.5 billion in Q4 2024, up 6455318.51% year-on-year from N/an in Q1 2024, and up 6455318.51% quarter-over-quarter from -$750560.0 in Q4 2023.

Immuron has reported Other Non Operating Income for 7 years, with the latest figure at $48.5 billion in Q4 2024.

  • For the quarter ending Q4 2024, Other Non Operating Income rose 6455318.51% year-over-year to $48.5 billion; the trailing twelve-month figure through Dec 2024 stood at $48.4 billion (up 5436655.64% YoY), and the FY2025 full-year result was $7896.2, up 143.62% from the prior year.
  • Other Non Operating Income for Q4 2024 stood at $48.5 billion, up from -$750560.0 in the prior quarter.
  • The five-year high for Other Non Operating Income was $48.5 billion in Q4 2024, with the low at -$750560.0 in Q4 2023.
  • Average Other Non Operating Income over 5 years is $9.7 billion, with a median of -$8736.3 recorded in 2020.
  • Year-over-year, Other Non Operating Income slumped 13755.82% in 2022 and jumped 6455318.51% in 2024.
  • Tracing IMRN's Other Non Operating Income over 5 years: stood at -$8736.3 in 2020, then jumped by 89.18% to -$945.0 in 2021, then tumbled by 13755.82% to -$130937.0 in 2022, then tumbled by 473.22% to -$750560.0 in 2023, then soared by 6455318.51% to $48.5 billion in 2024.
  • The last three Other Non Operating Income figures came in at $48.5 billion (Q4 2024), -$750560.0 (Q4 2023), and -$130937.0 (Q4 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Immuron 1.27 Bn 1.27 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 48.45 Bn
Dec 31, 2023 -750,560.00
Dec 31, 2022 -130,937.00
Dec 31, 2021 -945.00
Dec 31, 2020 -8,736.33
Dec 31, 2019 443.30
Dec 31, 2018 257,501.00